NasdaqGS - Delayed Quote • USD
ACADIA Pharmaceuticals Inc. (ACAD)
At close: April 25 at 4:00 PM EDT
After hours: April 25 at 7:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 19 | 19 | 20 | 20 |
| Avg. Estimate | 0.05 | 0.19 | 0.64 | 1.26 |
| Low Estimate | -0.08 | 0.11 | 0.3 | 0.79 |
| High Estimate | 0.17 | 0.27 | 0.97 | 2.16 |
| Year Ago EPS | -0.27 | 0.01 | -0.37 | 0.64 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 18 | 18 | 20 | 20 |
| Avg. Estimate | 208.36M | 241.81M | 967.32M | 1.09B |
| Low Estimate | 201.3M | 235.9M | 940.7M | 993.2M |
| High Estimate | 223.7M | 253M | 983.8M | 1.2B |
| Year Ago Sales | 118.46M | 157.81M | 726.44M | 967.32M |
| Sales Growth (year/est) | 75.90% | 53.20% | 33.20% | 13.10% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.21 | -0.08 | -0.43 | 0.3 |
| EPS Actual | -0.27 | 0.01 | -0.4 | 0.28 |
| Difference | -0.06 | 0.09 | 0.03 | -0.02 |
| Surprise % | -28.60% | 112.50% | 7.00% | -6.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.05 | 0.19 | 0.64 | 1.26 |
| 7 Days Ago | 0.05 | 0.2 | 0.66 | 1.27 |
| 30 Days Ago | 0.06 | 0.2 | 0.67 | 1.28 |
| 60 Days Ago | 0.2 | 0.33 | 1.04 | 1.8 |
| 90 Days Ago | 0.19 | 0.33 | 1.01 | 1.77 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | -- | -- |
| Up Last 30 Days | 1 | 1 | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 2 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | ACAD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 118.50% | -- | -- | 2.60% |
| Next Qtr. | 1,800.00% | -- | -- | 13.40% |
| Current Year | 273.00% | -- | -- | 5.20% |
| Next Year | 96.90% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -357.00% | -- | -- | 11.11% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/10/2024 |
| Reiterates | Needham: Buy to Buy | 4/9/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 3/25/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 3/13/2024 |
| Maintains | Citigroup: Buy to Buy | 3/12/2024 |
| Maintains | RBC Capital: Outperform to Outperform | 3/12/2024 |
Related Tickers
SAGE Sage Therapeutics, Inc.
13.58
-3.00%
INCY Incyte Corporation
51.18
-1.08%
AXSM Axsome Therapeutics, Inc.
71.52
+0.49%
CYTK Cytokinetics, Incorporated
64.80
-3.02%
DAWN Day One Biopharmaceuticals, Inc.
13.21
-13.03%
BCRX BioCryst Pharmaceuticals, Inc.
4.1600
-1.19%
MDGL Madrigal Pharmaceuticals, Inc.
194.38
-5.02%
BPMC Blueprint Medicines Corporation
90.73
-1.66%
BBIO BridgeBio Pharma, Inc.
24.33
-2.80%
ALNY Alnylam Pharmaceuticals, Inc.
143.71
-0.06%